{'fraction_non_alphanumeric': 0.024, 'fraction_numerical': 0.016, 'mean_word_length': 5.520833333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Predicting risk of relapse in endometrial hyperplasia

Endometrial cancer is the most common gynaecological malignancy amongst the developed world. The incidence of its precursor, endometrial hyperplasia, is estimated to be more than three times greater, and if left untreated, can progress to cancer (Reed et al. Am J Obstet Gynecol 2009;200:678). Successful treatment for endometrial hyperplasia has been found in the form of progestogens which modify the proliferative effects of unopposed oestrogen action on the endometrium, thus achieving disease regression. This article is protected by copyright. All rights reserved.